June 2022

肝障害および非アルコール性脂肪性肝炎時の従来型 合成、分子標的型合成、生物学的抗リウマチ薬による 関節リウマチ治療

Rheumatol Int. 2022 doi: 10.1007/s00296-022-05143-y

An increased incidence of liver diseases emphasizes greater caution in prescribing antirheumatic drugs, owing to their hepatotoxicity. However, drug-induced liver injury (DILI) in RA patients represents an aetiological and therapeutic challenge, due to the intertwining of inflammatory and metabolic elements mediated by IL-6 and TNF-α.

Keywords:

関節リウマチにおける生物学的製剤および低分子化合 物による実臨床での短期および長期的悪性腫瘍リスク

Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keab570

Observational, nationwide cohort study finds no increased risk for cancer overall in RA patients treated with TNFis, anti-CD20 or anti-IL6.

Keywords:

May 2022

関節リウマチ, 体軸型脊椎関節炎, 乾癬性関節炎, 乾癬 における生物学的製剤と疾患修飾薬の薬剤継続率– DANBIO および DERMBIO レジストリ

Semin Arthritis Rheum. 2022 doi: 10.1016/j.semarthrit.2022.151979

The authors reviewed drug survival of therapies across common inflammatory skin and joint conditions from national registries.  The findings highlighted that despite the overlapping pathogenesis of these conditions there was little similarity in drug survival. This reinforces the need for an individualised treatment approach consistent with the underlying disease, patient profile and treatment history.

Keywords:

April 2022

関節リウマチ関連間質性肺炎に対するJAK阻害薬または アバタセプトの効果を検討した後方視的研究

Inflammopharmacology. 2022. Epub ahead of print doi: 10.1007/s10787-022-00936-w

This study of the effectiveness of JAKinibs or abatacept in patients with RA-interstitial lung disease (RA-ILD) shows that treatment is related to stability or improvement of RA-ILD in over 80% of patients.

Keywords:

早期関節リウマチ患者におけるバリシチニブ単剤, バリシチニブとメトトレキサート併用, メトトレキサート 単剤による疼痛コントロール

RMD Open. 2022;8(1):e001994 doi: 10.1136/rmdopen-2021-001994

Post hoc analysis of the RA-BEGIN trial finds that, over a one-year period, patients treated with baricitinib (monotherapy or in combination with methotrexate [MTX]) report greater pain relief and a more rapid attainment of clinically meaningful thresholds of pain improvement, than patients who receive MTX monotherapy.Often overlooked, when treating RA solely to a disease activity target, patient-reported pain is common in RA, even in those reaching inflammatory remission. The fact that pain per...

Keywords:

ウパダシチニブ使用中の関節リウマチ患者における13価 肺炎球菌ワクチンに対する反応性評価: フェーズ2 オープンラベル延長試験結果

RMD Open. 2022;8(1):e002110 doi: 10.1136/rmdopen-2021-002110

Vaccine sub-study of the BALANCE-EXTEND upadacitinib trial finds that approximately two-thirds of patients receiving upadacitinib 15 mg once-daily achieve a satisfactory humoral response to pneumococcal 13-valent conjugate (PCV-13) vaccine, despite receiving concomitant methotrexate (MTX).It is well known that a weakened immune response, comorbidities and immunosuppressant drug therapy all contribute to an increased susceptibility to infections in patients with RA. Likewise, the morbidity and mo...

Keywords:

関節リウマチ患者の倦怠感、睡眠、健康関連QOLに対するトファシチニブの効果: フェーズ３試験結果の事後解析

Arthritis Res Ther. 2022;24(1):83 doi:10.1186/s13075-022-02724-x

This was an exploratory post hoc analysis of pooled data, from over 2000 patients in three Phase 3 studies of tofacitinib, which demonstrates an association between tofacitinib treatment and significantly greater improvements in fatigue, sleep, and health-related quality of life (HRQoL), compared with placebo.

Keywords:

March 2022

関節リウマチ患者においてバリシチニブは疾患活動性 に関連せず構造的破壊進行を抑制する抗リウマチ効果 を有する

Ann Rheum Dis. 2022. Epub ahead of print doi: 10.1136/annrheumdis-2021-221323

Baricitinib reduces structural damage progression versus placebo with background MTX and/or MTX, even in patients with moderate or high disease activity.In patients with RA, TNFi, IL-6i and rituximab have been shown to uncouple the link between disease activity and radiographic progression such that patients are protected from structural damage progression even if remission/low disease activity is not achieved.As such, Lopez-Romero, et al. aimed to evaluate if baricitinib further enhances diseas...

Keywords:

関節リウマチ患者におけるupadacitinib または adalimumab の3年間の長期有効性: SELECT-COMPARE 試験

RMD Open. 2022;8(1):e002012 doi: 10.1136/rmdopen-2021-002012

Upadacitinib continues to show consistently better clinical responses, compared with adalimumab, through 3 years, including rates of remission and low disease activity, physical function and pain severity.Following the favourable upadacitinib efficacy data seen in the SELECT-COMPARE study at 72 weeks, Fleischmann, et al. assessed the long-term safety and efficacy of upadacitinib versus adalimumab over 3 years in the long-term extension of this study, with promising results. ...

Keywords:

February 2022

関節リウマチ患者におけるトファシチニブの用量調節の有効 性と安全性に対する影響: オープンラベル長期延長試験の post hoc 解析 (ORAL Sequel)

Clin Rheumatol. 2022 Jan 1. Epub ahead of print doi: 10.1007/s10067-021-05908-z

Post-hoc analysis shows that dosing up from tofacitinib 5 to 10 mg BID is associated with improved efficacy for up to 12 months, versus staying on 5 mg BID, and dosing down from 10 to 5 mg BID is not generally associated with a significant loss of efficacy.Although clinical trials have generally shown no significant differences, in terms of efficacy and safety, when switching tofacitinib dose up or down, these per-protocol switches are not directly informative for clinical decision-making in dai...

Keywords: